Follicum announce today that the synthesis of the peptide has been completed. The peptide is the active ingredient of the product planned to be used in the clinical Phase I/IIa study. Production of product for the clinical Phase I/IIa study Follicum announced in early June that the company had signed an agreement with the peptide […]
Follicum’s half-year report 2015 (1 January to 30 June) is now published. Click here to open the report (in Swedish).
Follicum announce today that a joint cooperation agreement has been signed with PolyPeptide Group and Recipharm AB in anticipation of the clinical trials which are estimated to start in the beginning of 2016. Read more here.
Follicum’s financial report for the first quarter 2015 (1 January to 31 March) is now published. Click here to open the report (in Swedish).
Follicum announces that they have had a successful scientific advisory meeting with BfArM – the Federal Institute for Drugs and Medical Devices in Germany. BfArM did not have any major questions or objections to the material that Follicum presented, which indicates that, given nothing unpredicted occurs in the tox studies, Follicum may start a clinical […]
Yesterday, 29 April 2015, Follicum AB held their Annual General Meeting. The meeting resolved to adopt the presented income statement and balance sheet as well as to dispose of the company’s profit according to the Board’s proposal in the Annual Report. Furthermore, the meeting decided that no dividend will be paid for fiscal year 2014. […]
Follicum’s Annual Report for the financial year 2014 is now published in Swedish on the company’s website (Swedish version). It is also available in Follicum’s office at Scheelevägen 22, Lund. For more information please contact: Dr Jan Alenfall, CEO Follicum AB Tel +46 46 19 21 97 Email firstname.lastname@example.org
Follicum AB’s Annual General Meeting will take place on April 29 2015 at 16.00 at Scheelevägen 22 in Lund. The meeting will be held in Swedish. Click here to open the document Kallelse till årsmöte (in Swedish).
Follicum announced in February 2015 that they had finished two smaller toxicity studies with favorable results. The company has now started two larger toxicity studies which will finish in August 2015. These toxicity studies are necessary to get the authorities’ approval for clinical studies. For more information please contact Dr Jan Alenfall – CEO, Follicum […]
Follicum has now finished an important preclinical study on human scalp skin biopsies which have been transplanted to SCID-mice (mice with compromised immunological defence where human skin can survive and grow). The results are all in line with the findings which previously have been communicated after short-term in vitro studies on parts of human skin performed by […]